| 24.11 0.06 (0.25%) | 12-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 28.26 | 1-year : | 33.01 |
| Resists | First : | 24.2 | Second : | 28.26 |
| Pivot price | 23.54 |
|||
| Supports | First : | 23.15 | Second : | 22.51 |
| MAs | MA(5) : | 23.9 |
MA(20) : | 23.56 |
| MA(100) : | 24.97  |
MA(250) : | 0 | |
| MACD | MACD : | -0.1 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 96.5 |
D(3) : | 91.5 |
| RSI | RSI(14): 55.5 |
|||
| 52-week | High : | 30.45 | Low : | 22.04 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ FMS ] has closed below upper band by 14.2%. Bollinger Bands are 32.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 24.13 - 24.21 | 24.21 - 24.29 |
| Low: | 23.75 - 23.84 | 23.84 - 23.94 |
| Close: | 23.95 - 24.09 | 24.09 - 24.24 |
Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of February 23, 2022, it operated 4,171 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
Mon, 22 Dec 2025
Fresenius Medical Care AG : Release of a capital market information - TradingView — Track All Markets
Wed, 10 Dec 2025
Fresenius Medical Care appoints Charles Hugh-Jones as Global Chief Medical Officer and member of the Management Board - PR Newswire
Fri, 28 Nov 2025
An excellent week for Fresenius Medical Care AG's (ETR:FME) institutional owners who own 42% as one-year returns inch higher - Yahoo Finance
Tue, 04 Nov 2025
Fresenius Medical Care AG (FMS) Q3 2025 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Wed, 01 Oct 2025
Fresenius Medical Care appoints Joseph Turk as new Management Board Member for Care Enablement - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Care Facilities
|
|
| Shares Out | 580 (M) |
| Shares Float | 205 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 8 (%) |
| Shares Short | 767 (K) |
| Shares Short P.Month | 1,660 (K) |
| EPS | 1.42 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 52.43 |
| Profit Margin | 3.6 % |
| Operating Margin | 10.2 % |
| Return on Assets (ttm) | 3.3 % |
| Return on Equity (ttm) | 6.3 % |
| Qtrly Rev. Growth | 2.5 % |
| Gross Profit (p.s.) | 8.46 |
| Sales Per Share | 33.87 |
| EBITDA (p.s.) | 4.22 |
| Qtrly Earnings Growth | 29.5 % |
| Operating Cash Flow | 2,510 (M) |
| Levered Free Cash Flow | 2,150 (M) |
| PE Ratio | 16.86 |
| PEG Ratio | 0 |
| Price to Book value | 0.45 |
| Price to Sales | 0.71 |
| Price to Cash Flow | 5.56 |
| Dividend | 0.81 |
| Forward Dividend | 0 |
| Dividend Yield | 3.3% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|